Mary-Louise Hoffman
Vencore has formed a joint venture with Havas Health to offer data analytics and predictive modeling services intended to help biopharmaceutical companies gain insight into the rare-disease market.
HVH Patient Precision Analytics aims to collect, aggregate and analyze huge amounts of healthcare data to help clients identify people with rare diseases as well as to aid early diagnosis and treatment of those patients, Vencore said Wednesday.
Steve Costalas, a senior vice president and general counsel of Vencore, will lead HVH as CEO and Jeff Ceitlin, managing director at Havas Health, will serve as chief commercial officer of the new entity.
Costalas said the company aims to leverage its defense-grade patient finder technology to support customers in the pharmaceutical sector through the HVH venture.
